Advances in laboratory detection methods and technology application of SARS-CoV-2

Xiucai Zhang | Hanyan Meng | Huihui Liu | Qing Ye

The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, Hangzhou, China

Correspondence
Qing Ye, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, Hangzhou 310052, China.
Email: qingye@zju.edu.cn

Funding information
Key Project of Provincial Ministry Co-construction, Health science and Technology Project Plan of Zhejiang Province, Grant/Award Number: WKJ-ZJ-2128; Key Laboratory of Women’s Reproductive Health Research of Zhejiang Province, Grant/Award Number: ZDFY2020-RH-0006; The National Natural Science Foundation of China, Grant/Award Number: U20A20351; Key Research and Development Plan of Zhejiang Province, Grant/Award Number: 2021C03079

Abstract
At present, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is raging worldwide, and the coronavirus disease 2019 outbreak caused by SARS-CoV-2 seriously threatens the life and health of all humankind. There is no specific medicine for novel coronavirus yet. So, laboratory diagnoses of novel coronavirus as soon as possible and isolation of the source of infection play a vital role in preventing and controlling the epidemic. Therefore, selecting appropriate detection techniques and methods is particularly important to improve the efficiency of disease diagnosis and treatment and to curb the outbreak of infectious diseases. In this paper, virus nucleic acid, protein, and serum immunology were reviewed to provide a reference for further developing virus detection technology to provide better prevention and treatment strategies and research ideas for clinicians and researchers.

KEYWORDS
antigen, NAAT, SARS-CoV-2, sequencing, serum

1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19) refers to pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is mainly spread through respiratory droplets and close contact, and people are generally susceptible.1,2 According to the "novel coronavirus Diagnosis and Treatment Program (Trial Eighth Revision)" issued by the National Health and Health Commission, the virus is contagious during the incubation period. Since the outbreak of COVID-19 in December 2019, all walks of life around the world have made efforts to cope with it in various aspects (Figure 1). However, at present, COVID-19 still has no specific and effective treatment plan, and a vaccine against the mutant strain is still under development. Early diagnosis and timely isolation are the keys to preventing the further spread of the epidemic. In this paper, the latest progress in laboratory detection methods of SARS-CoV-2 was reviewed to provide some ideas for better and more accurate identification of SARS-CoV-2.

2 | NUCLEIC ACID DETECTION OF SARS-CoV-2

COVID-19 nucleic acid detection is the most widely used detection method for SARS-CoV-2. Commonly used nucleic acid detection methods include real-time fluorescence quantitative polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP) technology, second-generation sequencing (NGS) technology, and so on.3,4 Different nucleic acid detection methods have different characteristics and application values.
2.1 | Real-time reverse transcription-PCR

The reverse transcription-PCR (RT-PCR) process of SARS-CoV-2 includes specimen collection, specimen transportation to the laboratory, specimen lysis, virus RNA extraction and purification, RT-PCR amplification, detection, and analysis. The samples were lysed before RT-PCR amplification, and nucleic acids were extracted to remove potential inhibitors that might hinder target amplification. Both lysis/extraction and RT-PCR amplification can be performed by manually processing the instrument or automated operation. The detection rate of RT-PCR is different in patients with different specimens of COVID-19. As shown in Table 1, the detection rate of bronchoalveolar lavage fluid, sputum, rectal swabs, and nasopharyngeal swabs was higher by RT-PCR. However, the detection rate of the virus in blood and urine samples is meager.

The RT-PCR of SARS-CoV-2 has the characteristics of high sensitivity, strong specificity, rapidity and accuracy, and mature technology, which is widely used in the screening of SARS-CoV-2. However, it is necessary to strictly control the quality control of sample collection, detection, result interpretation, and so forth. In addition, to avoid false positive- or false-negative results, misdiagnosis or missed diagnosis may occur.

2.2 | Isothermal amplification technology

Except for RT-PCR, NAAT research has been launched to develop portable and rapid diagnostic tests for SARS-CoV-2. Isothermal amplification (IAT) replaces the high-temperature melting step in PCR with special enzymes. As it can be carried out under constant temperature, it does not need expensive equipment such as a thermal cycler. The principle of IATs is thermal denaturation or enzymatic denaturation of nucleic acids, followed by the nucleic acid amplification reaction. Isothermal NAAT technology includes transcription-mediated amplification (TMA), nick enzyme-assisted reaction (NEAR), LAMP, reverse transcription-recombinase polymerase amplification (RPA), and repeating CRISPR–Cas-related systems with short palindromes at regular intervals. The following sections describe examples of IAT and its current and potential applications.

2.2.1 | Reverse transcription-recombinase polymerase amplification

The reaction mechanism of RT-RPA is relatively simple, but the reaction components are relatively complex. Unlike RT-PCR, RT-RPA does not need complex instruments such as thermal cyclers, thus simplifying the detection process. The ease of use of this isothermal technique makes RT-RPA an attractive candidate for molecular testing. RT-RPA technology has been applied to the detection of other RNA viruses, such as the Ebola virus. However, to date, the data used to detect SARS-CoV-2 are not perfect.

Kim et al. used modified RT-RPA to detect SARS-CoV-2 and achieved a sensitivity of approximately four copies/reaction in a 10-minute reaction using lateral flow immunoassay (LFIA) readings. Their RT-RPA correctly identified 18 artificial samples produced by adding heat-inactivated virus to flocked nasopharyngeal swabs or saliva. Xia and Chen described another improved single-tube RT-RPA version introduced by GenDx, called reverse transcriptase recombinase amplification, and the whole packaging procedure of exponential amplification from RNA.
## Table 1: Real-time fluorescence quantitative PCR for the detection of various specimen types from confirmed patients with COVID-19

| Author of article | Types of research | Specimen type                  | Positive number | Total specimens | Positive rate |
|-------------------|-------------------|--------------------------------|-----------------|-----------------|--------------|
| Wang et al.6       | Cross-sectional study | Bronchoalveolar lavage fluid | 14              | 15              | 93.3%        |
|                   |                    | Bronchoscopic brush biopsy    | 6               | 13              | 46.2%        |
|                   |                    | Phlegm                         | 75              | 104             | 72.1%        |
|                   |                    | Nasal swab                     | 5               | 8               | 62.5%        |
|                   |                    | Swallow swab                   | 126             | 398             | 31.7%        |
|                   |                    | Phlegm                         | 75              | 104             | 72.1%        |
|                   |                    | Nasal swab                     | 5               | 8               | 62.5%        |
|                   |                    | Swallow swab                   | 126             | 398             | 31.7%        |
|                   |                    | Blood                          | 3               | 307             | 1.0%         |
|                   |                    | Urine                          | 0               | 72              | 0.0%         |
| Chen et al.7      | Retrospective study | Swallow swab                   | 65              | 167             | 38.9%        |
|                   |                    | Sputum                         | 155             | 206             | 75.2%        |
|                   |                    | Night soil                     | 17              | 64              | 26.6%        |
| Xu et al.8        | Prospective research | Swallow swab                   | 22              | 49              | 44.9%        |
|                   |                    | Rectal swab                    | 43              | 49              | 87.8%        |
| Chan et al.9      | Case report         | Nasopharyngeal swab            | 4               | 5               | 80.0%        |
|                   |                    | Swallow swab                   | 2               | 3               | 66.7%        |
|                   |                    | Sputum                         | 2               | 2               | 100.0%       |
|                   |                    | Serum                          | 1               | 3               | 33.3%        |
|                   |                    | Blood plasma                   | 0               | 4               | 0.0%         |
|                   |                    | Urine                          | 0               | 5               | 0.0%         |
|                   |                    | Night soil                     | 0               | 4               | 0.0%         |
| Lo et al.10       | Perspective study  | Nasopharyngeal swab            | 57              | 84              | 67.9%        |
|                   |                    | Sputum                         | 1               | 1               | 100.0%       |
|                   |                    | Urine                          | 0               | 49              | 0.0%         |
|                   |                    | Night soil                     | 46              | 79              | 58.2%        |
| Mishra et al.11   | Retrospective study | Saliva                         | 58              | 250             | 23.2%        |
|                   |                    | Urine                          | 8               | 318             | 2.5%         |
|                   |                    | Night soil                     | 396             | 779             | 50.8%        |
|                   |                    | Blood                          | 7               | 21              | 33.3%        |
| Summary           |                    | Bronchoalveolar lavage fluid   | 14              | 15              | 93.3%        |
|                   |                    | Bronchoscopic brush biopsy     | 6               | 13              | 46.2%        |
|                   |                    | Sputum                         | 233             | 313             | 74.4%        |
|                   |                    | Nasal swab                     | 5               | 8               | 62.5%        |
|                   |                    | Swallow swab                   | 215             | 617             | 34.8%        |
|                   |                    | Night soil                     | 503             | 1079            | 46.6%        |
|                   |                    | Blood                          | 10              | 328             | 3.0%         |
|                   |                    | Urine                          | 8               | 444             | 1.8%         |
|                   |                    | Nasopharyngeal swab            | 61              | 89              | 68.5%        |
|                   |                    | Rectal swab                    | 43              | 49              | 87.8%        |
|                   |                    | Serum                          | 1               | 3               | 33.3%        |
|                   |                    | Blood plasma                   | 0               | 4               | 0.0%         |
|                   |                    | Saliva                         | 58              | 250             | 23.2%        |

Abbreviations: COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction.
2.2.2 | Transcription-mediated amplification

TMA is an IAT that amplifies RNA from an RNA template.16,17 This technology has been applied to high-throughput analyzers for SARS-CoV-2 diagnosis.18–20 In this paper, through the search and collation of relevant literature, some research on the diagnosis of SARS-CoV-2 by TMA technology is also analyzed and experimented with. Details are shown in Table 2.

2.2.3 | Nick enzyme-assisted reaction

The NEAR amplification reaction occurs under isothermal conditions and can be divided into duplex formation and products. The mechanism of NEAR amplification of nucleic acids is relatively complex, but the detection process is rapid and straightforward, and the processing time is as low as 5–15 min. Compared with LDT or commercial NAAT, many recent studies have shown that the consistency of specificity/negative percentage in detecting SARS-CoV-2 by NEAR technology is close to 100%. However, the sensitivity/positive percentage consistency is relatively poor, ranging from 48% to 70%. Other studies have reported a high specificity/NPA (~100%) and sensitivity/PPA value higher than 90%.24

2.2.4 | Reverse transcription-loop-mediated isothermal amplification

RT-LAMP is a new isothermal nucleic acid amplification technology attracting attention.25 Similar to RT-PCR, RT-LAMP first transcribes target RNA into cDNA by reverse transcriptase and then carries out an amplification reaction. As this technology can use different primers to amplify multiple target sequences in the same reaction exponentially, it has high detection efficiency, strong specificity, and sensitivity. Meanwhile, expensive reagents or instruments are not needed, which is helpful to reduce the detection cost of COVID-19 nucleic acid and improve detection efficiency. A commercial kit for real-time SARS-CoV-2 RT-LAMP was developed and compared with RT-PCR. The results of the commercial RT-LAMP kit were consistent with those of RT-PCR, and the clinical sensitivity was 76.3%.26,27 Due to its simplicity, RT-LAMP technology is also used to develop rapid POCT products. With this technology, the results can be obtained within 30 min.

Compared with RT-PCR, when tested on 21 nasal swabs, the sensitivity was 80%, and the specificity was 73%, which was relatively low.28 The authors of this study believed that although the sensitivity and specificity are poor, the analysis is still valuable in some clinical applications. Other studies using RT-LAMP show that compared with LDT based on RT-PCR, the performance of common sample types using RT-LAMP is different.29 Generally, the range of reaction copies is consistent with some LDT and commercial RT-PCR results. Due to the high sensitivity of LAMP technology, aerosol pollution easily occurs during the experiment, which leads to false positives. In addition, this method has relatively high requirements for primer design, which is developed late, and the technology is not mature enough. There was no difference between LAMP operation, personal protection, laboratory requirements, and RT-PCR. However, the amplification time of LAMP is greatly reduced, so the exposure time of operators is reduced.

2.2.5 | CRISPR–Cas technology

Gene-editing technology can modify and edit genes or transcripts in organisms at fixed points and achieve the function of detecting pathogens by identifying specific sequences in test samples. The CRISPR–Cas system represents this technology. CRISPR and its Cas protein are derived from the photonic defense system against foreign nucleic acids.30

### Table 2: Performance verification of transcription-mediated amplification technology in the diagnosis of SARS-CoV-2

| Author of article | Research method | Specimen type | Number of specimens | Positive coincidence rate | Negative coincidence rate |
|-------------------|-----------------|---------------|---------------------|--------------------------|--------------------------|
| Pham et al.21      | Hologic Panther Fusion | Nasopharyngeal swab | 140 | 100% | 98.7% |
| Schneider et al.22 | Hologic Aptima   | Upper respiratory tract specimen | 103 | 95.7% | - |
| Smith et al.19     | Hologic Panther Fusion | Nasopharyngeal swab | 150 | 98.7% | 100% |
|                    | Hologic Aptima   | Nasopharyngeal swab | 150 | 94.7% | 100% |
|                    | BioFire Defense  | Nasopharyngeal swab | 150 | 98.7% | 100% |
| Cordak et al.23    | Hologic Aptima   | Upper respiratory tract specimen | 157 | 99.4% | 99% |
| Summary            | Hologic Panther Fusion | Nasopharyngeal swab | 290 | 99.3 | 99.3 |
|                    | Hologic Aptima   | Upper respiratory tract specimen | 260 | 95.8 | - |
|                    | Nasopharyngeal swab | 150 | 94.7 | 100% |
| BioFire Defense    | Nasopharyngeal swab | 150 | 98.7% | 100% |

Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
When activated, the Cas protein can show local DNase or RNase activity, which leads to local cleavage of target DNA or RNA (cis-cleavage) and incidental damage to adjacent single-stranded DNA or RNA (trans-cleavage). By cutting RNA or DNA from a band, the detection result is visually visible, and the purpose of diagnosis is achieved.

It has become an active research direction to apply CRISPR–Cas technology to SARS-CoV-2, but its analytical performance needs further verification. Studies have shown that CRISPR-based detection can identify SARS-CoV-2 at a low viral load. In summary, the data show the difference in detection performance based on CRISPR, and the sensitivity ranges from 80% to 100%. Although further verification is needed to fully understand the advantages of CRISPR–Cas technology, it has great potential in applying POCT equipment or a high-throughput test platform. In addition, if CRISPR-CAS technology is combined with recombinant polymerase amplification technology, it can amplify a large number of trace nucleic acids in samples at a constant temperature and has the advantages of simple operation, high sensitivity, and fast detection speed, which may compensate for the shortcomings of other existing technologies.

The above IAT techniques have advantages and disadvantages in experimental operation and effect, among which RT-RPA does not need complex instruments such as thermal cyclers. The detection process is simplified. At present, the data used for detecting SARS-CoV-2 by this method are not perfect. Compared with RT-PCR, TMA technology has similar sensitivity and detection coincidence rate and relatively high accuracy. Its clinical performance is worth looking forward to. The specificity of the NEAR technique for SARS-CoV-2 detection is close to 100%, but the sensitivity is relatively poor, which needs further optimization. RT-LAMP technology does not need expensive instruments and is easy to operate to develop rapid POCT products. However, aerosol pollution and false positives easily occur when the cap is opened in the experimental process, and it has high requirements for primer design. Technology is not yet mature: CRISPR–Cas technology has high efficiency and low cost, but the CRISPR/Cas system has occasional off-target effects. Experimental personnel should wear protective articles for biosafety level 3 laboratories and complete nucleic acid extraction in biosafety cabinets with biosafety level 2 laboratories. Subsequent fluorescence detection was carried out on the CRISPR platform without opening the cover again. It can effectively ensure the safety of operators.

2.3 Genome sequencing-SARS-CoV-2 NGS

Gene sequencing technology has been successfully applied to identify unknown viruses, conducive to our rapid response to the outbreak of new infectious diseases. Scientists in China isolated SARS-CoV-2 from patients at the early stage of the outbreak using the metagenomics technology of NGS sequenced it and provided the sequence to the World Health Organization on December 12, 2020. It was conducive to the global response to the epidemic. For the 30 kb SARS-CoV-2 genome, NGS can quickly obtain high-quality sequences directly from clinical specimens, and strategies such as amplification enrichment or bait capture are used to facilitate the sequencing of the virus targets. NGS involves synthetic sequencing, ligation sequencing, and ion semiconductor sequencing, each with its advantages and limitations.

According to FDA EUA guidelines, a single commercial kit for atypical pneumonia (Illumina, Inc.) has been approved as a clinical diagnostic test in COVID-19, which is based on synthetic sequencing. However, there are no data to describe its performance, advantages, or limitations compared with standard detection methods such as RT-PCR. In addition, only a limited number of studies have explored the purpose of NGS for SARS-CoV-2 detection. For example, using the NGS protocol developed by the laboratory, Bhoyar et al. compared the results of repeated treatment of 752 clinical specimens by NGS and real-time fluorescence quantitative RT-PCR on single flow cells. The coincidence rate of the two methods was very high, and the positive rate of NGS diagnosis increased by 5.7% (6 cases were negative by PCR, and 21 cases were uncertain by PCR). This study demonstrated the feasibility of processing 1536 samples in a total of 17 h (11 h for sequencing and 6 h for analysis) in another study, a low-cost NGS method proved to be highly sensitive to SARS-CoV-2, and its sensitivity was equal to or higher than that of some RT-PCR methods. However, only 10 samples (five positive samples and five negative samples) were tested in this study. If the flux is increased to their proposed workflow of 192 samples within 8 h, it is unclear whether high sensitivity will still occur. Compared with limited samples (31 positives and 33 negatives), the coincidence rate between NGS and RT-PCR was 100%. Generally, some data support the potential of NGS as a diagnostic tool for SARS-CoV-2, but further analysis is needed to understand its advantages and limitations.

In summary, NGS is conducive to the initial identification and in-depth study of SARS-CoV-2, and its accuracy is very high. However, NGS requires more equipment, takes more time and costs, and is unsuitable for rapid clinical screening.

2.4 Detection of SARS-CoV-2 antigen

Antigen detection methods, such as NAAT, detect active replication viruses in the early stage of SARS-CoV-2 infection. Antigen detection is mainly based on two antigens in SARS-CoV-2 detection, namely, the S protein and N protein. High-throughput antigen-based detection can be performed on semiautomatic or automated instruments using enzyme immunosassay technology. SARS-CoV-2 AG-RDT is usually advertised as POCT equipment and used for rapid testing and instant management of patients in doctor’s offices or clinics. Examples approved in laboratories or POCT environments in the United States or Canada include relying on colorimetric LFIA with visual readings, antigen detection using fluorescence-based LFIA, microfluidic immunofluorescence analysis chromatographic digital immunoassay, and so forth.

Although EUA has approved some AG-RDTs and high specificity has been observed in antigen-based detection methods, the sensitivity of AG-RDTs is low (Table 3). Seo et al. studied a biosensor based on a field-effect transistor, which can detect SARS-CoV-2 with
a concentration of $2.42 \times 10^2$ copies/ml in clinical specimens in approximately 3 min without sample pretreatment. Antigen detection is suitable for early detection and has the characteristics of rapid detection without expensive equipment and laboratories, and the false positive rate of detection results is also low.

### TABLE 3 Performance verification of table antigen detection technology in SARS-CoV-2 diagnosis

| Research method     | Sample number or sample size | Average sensitivity | Average specificity | References |
|---------------------|-----------------------------|---------------------|---------------------|------------|
| Antigen detection   | 328                         | 57.6                | 99.5%               | 37         |
| Antigen detection   | 148                         | 30.2                | –                   | 38         |
| Antigen detection   | $1.8 \times 10^5$ copies/ml | 100%                | –                   | 39         |
| Antigen detection   | $9.4 \times 10^3$ copies/ml | 70.6%               | –                   | 39         |
| Antigen detection   | $4.9 \times 10^2$ copies/ml | 46.9%               | –                   | 39         |
| Antigen detection   | 138                         | 50%                 | 100%                | 40         |

Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

### TABLE 4 Performance verification of serological detection technology in SARS-CoV-2 diagnosis

| Research method | Detection object | Onset time | Average sensitivity | Average specificity | References |
|-----------------|------------------|------------|---------------------|---------------------|------------|
| LFIA            | IgM              | Week 1     | 25.3%               | –                   | 42         |
|                 |                  | Week 2     | 51.8%               | –                   | 42         |
|                 |                  | Week 3     | 69.9%               | –                   | 42         |
|                 | IgG              | Week 1     | 13.4%               | –                   | 42         |
|                 |                  | Week 2     | 50.1%               | –                   | 42         |
|                 |                  | Week 3     | 79.7%               | –                   | 42         |
| ELISA           | IgM              | Week 1     | 26.7                | –                   | 39         |
|                 |                  | Week 2     | 57.6%               | –                   | 39         |
|                 |                  | Week 3     | 78.4%               | –                   | 39         |
|                 | IgG              | Week 1     | 23.7%               | –                   | 39         |
|                 |                  | Week 2     | 65.3%               | –                   | 39         |
|                 |                  | Week 3     | 82.1%               | –                   | 39         |
| CLIA            | IgM              | Week 1     | 50.3%               | –                   | 39         |
|                 |                  | Week 2     | 74.3%               | –                   | 39         |
|                 |                  | Week 3     | 90.6%               | –                   | 39         |
|                 | IgG              | Week 1     | 53.2%               | –                   | 39         |
|                 |                  | Week 2     | 85.4%               | –                   | 39         |
|                 |                  | Week 3     | 98.9%               | –                   | 39         |
| LFIA            | IgM              | –          | 61.8%               | 96.6%               | 39         |
|                 | IgG              |            | 64.9%               | 97.6%               | 39         |
| ELISA           | IgM              |            | 81.7%               | 99.7%               | 39         |
|                 | IgG              |            | 80.6%               | 98.9%               | 39         |
| CLIA            | IgM              |            | 84.3%               | 96.6%               | 39         |
|                 | IgG              |            | 93.5%               | 97.8%               | 39         |

Abbreviations: CLIA, chemiluminescence; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; IgM, immunoglobulin M; LFIA, lateral flow immunoassay; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

### 2.5 Serological immunological methods for the detection of SARS-CoV-2

SARS-CoV-2 infection can stimulate the body to produce specific antibodies. This means that the laboratory can detect SARS-CoV-2-specific
antibodies in blood sources such as serum, plasma, or whole blood based on the immunological principle of antigen-antibody specific binding. Given that the typical time of detecting the SARS-CoV-2 immune response is approximately 1–2 weeks, serological detection has a limited diagnostic effect on SARS-CoV-2 in the acute stage of disease, but it may be valuable once the immune response occurs in time. Commonly used methods include enzyme-linked immunosorbent assay, chemiluminescence (CLIA), and LFIA. According to a meta-systematic evaluation and meta-analysis published in the past, we summarized the sensitivity and specificity of the three methods as follows (Table 4). The sensitivity of the three methods is related to the duration of onset, and the sensitivity of the three methods in the third week of onset is higher than that in the first 2 weeks. The CLIA method is the most sensitive of the three serological detection methods, and the specificity is not much different.

The diagnosis of SARS-CoV-2 is mainly based on nucleic acid detection and gene sequencing. However, nucleic acid detection will be affected by many factors, such as the infection cycle of patients, specimen types, specimen collection methods, specimen preservation, and transportation conditions, and the performance of detection kits, and false positives or false negatives may occur. In addition, gene sequencing has high requirements for equipment, a long time, and high cost. It is not suitable for the rapid screening of large clinical samples. Serum immunological technology can be used to supplement molecular biology technology to increase the accuracy and reliability of SARS-CoV-2 detection. For example, when the SARS-CoV-2 test is false negative or the infection time is long, it can be combined with SARS-CoV-2 specific antibody (immunoglobulin M/immunoglobulin G [IgM/IgG]) detection results in serum to determine whether it has been infected with SARS-CoV-2 recently or in the past. This method is helpful for the diagnosis of nucleic acid-negative but clinically suspected cases. According to the "novel coronavirus Diagnosis and Treatment Plan (Seventh Edition)," the detection of specific antibodies in serology has been included in the diagnosis basis of SARS-CoV-2 infection.

Serum immunological detection has the characteristics of high efficiency and high specificity and can be used as a powerful auxiliary diagnostic method. However, the detection of antibodies will be affected by some interfering substances in blood samples, such as rheumatoid factor, antinuclear antibody, nonspecific IgM, and so forth, making false-positive results. Therefore, it is necessary to detect IgM and IgG simultaneously and improve the accuracy through multiple dynamic monitoring.

3 | CONCLUSIONS

Under the background of the current epidemic situation in COVID-19, it is still the most important task to develop diagnostic reagents and methods with high sensitivity, high specificity, low cost, easy operation, and short time. Figure 2 is the mode diagram of the detection technology summarized in this study. Real-time fluorescence quantitative PCR has become the gold standard for SARS-CoV-2 detection because of its high sensitivity and strong specificity. However, it is easy to have false negatives due to various factors. How to solve the problem of false negatives is worth considering. LAMP and CRISPR/Cas have apparent advantages in nucleic acid quantification and sensitivity. Sequencing technology is reliable, but it needs expensive instruments and high-tech personnel, so it is not widely used at the grassroots level. Antibody detection assists the detection of SARS-CoV-2 to some extent. In addition, facing the problem of virus traceability, countries worldwide need to work together to develop new detection methods and technologies that are more efficient, more accurate, small, and cheap and provide genuinely effective prevention and control measures for all humankind to control the COVID-19 epidemic.

ACKNOWLEDGMENTS

This study was supported by the key project of provincial ministry coconstruction, Health Science and Technology project plan of
Zhejiang Province (WKJ-ZJ-2128), Key Laboratory of Women's Reproductive Health Research of Zhejiang Province (No. ZDFY2020-RH-0006), the National Natural Science Foundation of China (Grant/ Award Numbers: U20A20351), and Key Research and Development Plan of Zhejiang Province (Grant/Award Numbers: 2021CO3079).

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS
Qing Ye had the idea for and designed the study and took responsibility for the integrity of the data and the accuracy of the data analysis. Hanyan Meng and Huihui Liu contributed to the writing of the report. Xiucai Zhang and Hanyan Meng contributed to the critical revision of the report. Xiucai Zhang and Hanyan Meng contributed to the statistical analysis. All authors contributed to data acquisition, data analysis, or data interpretation and reviewed and approved the final version.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Qing Ye https://orcid.org/0000-0002-6756-0630

REFERENCES
1. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382(23):2475-2477.
2. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607-613.
3. Carter LJ, Gamer LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020;6(5):591-605.
4. Yu CY, Chan KG, Yean CY, Ang GY. Nucleic acid-based diagnostic tests for the detection SARS-CoV-2: an update. Diagnostics. 2021:11:53.
5. Datta M, Singh DD, Naqvi AR. Molecular diagnostic tools for the detection of SARS-CoV-2. Int Rev Immunol. 2021;40(1-2):143-156.
6. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-1844.
7. Chen C, Gao G, Xu Y, et al. SARS-CoV-2-positive sputum and feces after conversion of pharyngeal samples in patients with COVID-19. Ann Intern Med. 2020;172(12):832-834.
8. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502-505.
9. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.
10. Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;16(10):1698-1707.
11. Mishra C, Meena S, Meena JK, Tiwari S, Mathur P. Detection of three pandemic causing coronaviruses from non-respiratory samples: systematic review and meta-analysis. Sci Rep. 2021;11(1):16131.
12. James AS, Alawneh JI. COVID-19 infection diagnosis: potential impact of isothermal amplification technology to reduce community transmission of SARS-CoV-2. Diagnostics. 2020;10(6):399.
13. Li J, Macdonald J, von Stetten F. Review: a comprehensive summary of a decade development of the recombinase polymerase amplification. Analyst. 2018;144(1):31-67.
14. Kim Y, Yaseen AB, Kishi JY, et al. Single-strand RPA for rapid and sensitive detection of SARS-CoV-2 RNA. medRxiv [Preprint]. 2020. doi:10.1101/2020.08.17.20177006
15. Xia S, Chen X. Single-copy sensitive, field-deployable, and simultaneous dual-gene detection of SARS-CoV-2 RNA via modified RT-RPA. Cell Discov. 2020;6(1):37.
16. Buchan BW, Ledeboer NA. Emerging technologies for the clinical microbiology laboratory. Clin Microbiol Rev. 2014;27(4):783-822.
17. Giachetti C, Linnen JM, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol. 2002;40(7):2408-2419.
18. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays. J Clin Virol. 2020;130:104578.
19. Smith E, Zhen W, Manji R, Schron D, Duong S, Berry GJ. Analytical and clinical comparison of three nucleic acid amplification tests for SARS-CoV-2 detection. J Clin Microbiol. 2020;58(9):e01134-20.
20. Goralski AJ, Tian H, Lavenderde C, et al. High-throughput transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2. J Clin Virol. 2020;129:104501.
21. Pham J, Meyer S, Nguyen C, et al. Performance characteristics of a high-throughput automated transcription-mediated amplification test for SARS-CoV-2 detection. J Clin Microbiol. 2020;58(10):e01669-20.
22. Schneider M, Iftner T, Ganzenmueller T. Evaluation of the analytical performance and specificity of a SARS-CoV-2 transcription-mediated amplification assay. J Virol Methods. 2021;294:114182.
23. Cordes AK, Rehrauer WM, Accola MA, Wolk B, Hilfrich B, Heim A. Fully automated detection and differentiation of pandemic and endemic coronaviruses (NL63, 229E, HKU1, OC43 and SARS-CoV-2) on the hologic panther fusion. J Med Virol. 2021;93(7):4438-4445.
24. Zhen W, Smith E, Manji R, Schron D, Berry GJ. Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2. J Clin Microbiol. 2020;58(8):e00783-20.
25. Dunbar S, Das S. Amplification chemistries in clinical virology. J Clin Virol. 2019;115:18-31.
26. Rödel J, Egerer R, Suleyman A, et al. Use of the variplex SARS-CoV-2 RT-LAMP as a rapid molecular assay to complement RT-PCR for COVID-19 diagnosis. J Clin Virol. 2020;132:104616.
27. Eckel F, Kusters F, Drossel B, Konert M, Mattes H, Schopf S. Variplex test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction. Eur J Clin Microbiol Infect Dis. 2020;39(12):2373-2377.
28. Österdahl MF, Lee KA, Lochlann MN, et al. Detecting SARS-CoV-2 at point of care: preliminary data comparing loop-mediated isothermal amplification (LAMP) to polymerase chain reaction (PCR). BMC Infect Dis. 2020;20(1):783.
29. Baek YH, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):998-1007.
30. Wright AV, Nunez JK, Doudna JA. Biology and applications of CRISPR systems: Harnessing nature’s toolbox for genome engineering. Cell. 2016;164(1-2):29-44.
31. Broughton JP, Deng X, Yu G, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38(7):870-874.
32. Nasir JA, Kozak RA, Aftanas P, et al. A comparison of whole genome sequencing of SARS-CoV-2 using amplicon-based sequencing, random hexamers, and bait capture. Viruses. 2020;12(8):895.
33. Muzzey D, Evans EA, Lieber C. Understanding the basics of NGS: from mechanism to variant calling. Curr Genet Med Rep. 2015;3(4):158-165.

34. Shendure J, Porreca GJ, Reppas NB, et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science. 2005;309(5741):1728-1732.

35. Bhoyar RC, Jain A, Sehgal P, et al. High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing. PLoS One. 2021;16(2):e0247115.

36. Bloom JS, Sathe L, Munugala C, et al. Swab-Seq: a high-throughput platform for massively scaled up SARS-CoV-2 testing. medRxiv [Preprint]. 2021. doi:10.1101/2020.08.04.20167874

37. Mertens P, De Vos N, Martiny D, et al. Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context. Front Med. 2020;7:225.

38. Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol. 2020;129:104455.

39. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 2021;34(3):e00228-20.

40. Lambert-Niclot S, Cuffel A, Le Pape S, et al. Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs. J Clin Microbiol. 2020;58(8):e00977-20.

41. Krammer F, Simon V. Serology assays to manage COVID-19. Science. 2020;368(6495):1060-1061.

42. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for COVID-19: systematic review and meta-analysis. BMJ. 2020;370:m2516.

How to cite this article: Zhang X, Meng H, Liu H, Ye Q. Advances in laboratory detection methods and technology application of SARS-CoV-2. J Med Virol. 2022;94:1357-1365. doi:10.1002/jmv.27494